期刊文献+

肝脏慢性病毒感染对结直肠癌肝转移发生及生存影响

Effect of chronic hepatic virus infection on colorectal cancer liver metastases and survival
原文传递
导出
摘要 目的探讨肝脏慢性病毒感染对结直肠癌肝转移发生率影响,分析感染者和无感染者病例总体生存情况。方法回顾性研究2868例结直肠病例,根据外周血检测结果分为感染组和无感染组,比较两组患者肝转移发生率,分析两组患者总体生存情况及比较两组肝转移患者生存时间。结果两组病例肝转移发生率比较差异有统计学意义(P<0.05),5年总体生存率感染组优于无感染组,肝转移伴病毒感染组中位生存期26个月,无感染组20个月,两组比较差异有统计学意义(P<0.001)。结论肝脏慢性病毒感染可降低结直肠癌肝转移发生率,有肝脏慢性病毒感染者病例总体预后优于无感染组,肝转移患者伴肝脏慢性病毒感染预后较好。 Objective To investigate the effect of chronic hepatic virus infection on colorectal cancer liver metastases,and analysis the survival between infected group and non-infected group. Methods 2868 colorectal cancer patients were retrospectively analyzed. According to the peripheral blood test, patients were divided into infected group and non-infected group. The incidence of liver metastases and survival were compared, patients with liver metastases survival time were also compared. Results Significant differences were found between two groups (P 〈 0. 05 ), 5 years overall survival in infected group were better than control group. Colorectal cancer liver metastases with hepatic virus infection showed the median survival time 26 months, while the non-infected group 20 months. Conclusions Chronic hepatic virus infection decrease the risk of colorectal cancer liver metastases, also show the better oncology outcome for these patients. Colorectal cancer liver metastases with hepatic infection show better prognosis and longer survival time.
出处 《中华临床医师杂志(电子版)》 CAS 2012年第13期97-99,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 国家自然科学基金(81072046)
关键词 肝炎 慢性 结直肠肿瘤 肿瘤转移 Hepatitis,chronic Colorectal neoplasms Neoplasm metastasis
  • 相关文献

参考文献2

二级参考文献31

  • 1崔富强,王晓军,梁晓峰.中国≤15岁人群乙型病毒性肝炎发病流行病学分析[J].中国计划免疫,2006,12(3):206-208. 被引量:32
  • 2卢永,崔富强,王晓军,龚晓红,董红军,胡苑笙,陈园生,梁晓峰.中国八省市各级医疗机构确诊急性乙型肝炎实验室检测能力调查[J].中华流行病学杂志,2006,27(9):802-802. 被引量:22
  • 3Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007:1-50.
  • 4Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42:2212-2221.
  • 5Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Ma- honey MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorec- tal cancer: a North Central Cancer Treatment Group phase II study. J Clin Onco12005; 23:9243-9249.
  • 6FosterJH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis 1984; 4:170-179.
  • 7Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepatitis B in China. J Med Viro12002; 67:447-450.
  • 8De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer 2010; 46:2178-2186.
  • 9Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, Zhou H, Hao X. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatoceUular carcinomas related to HBV. Surg Oncol 2009; 18:25-30.
  • 10Utsunomiya T, Saitsu H, Saku M, Yoshida K, Matsumata T, Shimada M, Sugimachi K. Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg 1999; 177:279-281.

共引文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部